Is LXEO or MAZE more profitable?

Maze Therapeutics' return on equity of -34.94% beat Lexeo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Lexeo Therapeutics N/A -41.85% -38.03% Maze Therapeutics N/A -34.94% -30.18%

Does the media favor LXEO or MAZE?

In the previous week, Lexeo Therapeutics had 1 more articles in the media than Maze Therapeutics. MarketBeat recorded 2 mentions for Lexeo Therapeutics and 1 mentions for Maze Therapeutics. Lexeo Therapeutics' average media sentiment score of 0.67 beat Maze Therapeutics' score of -1.05 indicating that Lexeo Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexeo Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Maze Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative

Is ABSI or LXEO more profitable?

Lexeo Therapeutics has a net margin of 0.00% compared to Absci's net margin of -7,756.38%. Lexeo Therapeutics' return on equity of -41.85% beat Absci's return on equity. Company Net Margins Return on Equity Return on Assets Absci -7,756.38% -61.71% -54.52% Lexeo Therapeutics N/A -41.85% -38.03%

Does the media refer more to ABSI or LXEO?

In the previous week, Absci had 1 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 3 mentions for Absci and 2 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 0.67 beat Absci's score of 0.56 indicating that Lexeo Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Absci 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lexeo Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, LXEO or TRAX?

First Tracks Biotherapeutics is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lexeo Therapeutics N/A N/A -$99.96M -$1.15 N/A First Tracks Biotherapeutics N/A N/A N/A -$1.84 N/A

Is LXEO or TRAX more profitable?

First Tracks Biotherapeutics' return on equity of 0.00% beat Lexeo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Lexeo Therapeutics N/A -41.85% -38.03% First Tracks Biotherapeutics N/A N/A N/A

Does the media refer more to LXEO or TRAX?

In the previous week, First Tracks Biotherapeutics had 2 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 4 mentions for First Tracks Biotherapeutics and 2 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 0.67 beat First Tracks Biotherapeutics' score of 0.14 indicating that Lexeo Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexeo Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive First Tracks Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, LXEO or VOR?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lexeo Therapeutics N/A N/A -$99.96M -$1.15 N/A Vor Biopharma N/A N/A N/A N/A N/A

Is LXEO or VOR more profitable?

Vor Biopharma's return on equity of 0.00% beat Lexeo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Lexeo Therapeutics N/A -41.85% -38.03% Vor Biopharma N/A N/A N/A

Does the media prefer LXEO or VOR?

In the previous week, Lexeo Therapeutics and Lexeo Therapeutics both had 2 articles in the media. Lexeo Therapeutics' average media sentiment score of 0.67 beat Vor Biopharma's score of 0.00 indicating that Lexeo Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexeo Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vor Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor RARE or LXEO?

In the previous week, Ultragenyx Pharmaceutical had 34 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 36 mentions for Ultragenyx Pharmaceutical and 2 mentions for Lexeo Therapeutics. Ultragenyx Pharmaceutical's average media sentiment score of 0.74 beat Lexeo Therapeutics' score of 0.67 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ultragenyx Pharmaceutical 12 Very Positive mention(s) 7 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Lexeo Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Lexeo Therapeutics (LXEO) Competitors

$4.20 +0.02 (+0.48%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$4.20 0.00 (0.00%)

As of 09/18/2026 07:30 PM Eastern

Compare

LXEO vs. MAZE, ABSI, TRAX, VOR, and RARE

Should you buy Lexeo Therapeutics stock or one of its competitors? Lexeo Therapeutics's main competitors and comparable companies include Maze Therapeutics (MAZE), Absci (ABSI), First Tracks Biotherapeutics (TRAX), Vor Biopharma (VOR), and Ultragenyx Pharmaceutical (RARE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Lexeo Therapeutics compare to Maze Therapeutics?

Lexeo Therapeutics (NASDAQ:LXEO) and Maze Therapeutics (NASDAQ:MAZE) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment.

Maze Therapeutics' return on equity of -34.94% beat Lexeo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexeo Therapeutics	N/A	-41.85%	-38.03%
Maze Therapeutics	N/A	-34.94%	-30.18%

In the previous week, Lexeo Therapeutics had 1 more articles in the media than Maze Therapeutics. MarketBeat recorded 2 mentions for Lexeo Therapeutics and 1 mentions for Maze Therapeutics. Lexeo Therapeutics' average media sentiment score of 0.67 beat Maze Therapeutics' score of -1.05 indicating that Lexeo Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lexeo Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Maze Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative

Lexeo Therapeutics has a beta of 1.5, suggesting that its stock price is 50% more volatile than the broader market. Comparatively, Maze Therapeutics has a beta of 2.17, suggesting that its stock price is 117% more volatile than the broader market.

Lexeo Therapeutics presently has a consensus target price of $18.75, suggesting a potential upside of 346.43%. Maze Therapeutics has a consensus target price of $66.00, suggesting a potential upside of 193.07%. Given Lexeo Therapeutics' higher probable upside, equities research analysts plainly believe Lexeo Therapeutics is more favorable than Maze Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	3 Strong Buy rating(s)	3.08

60.7% of Lexeo Therapeutics shares are owned by institutional investors. 2.0% of Lexeo Therapeutics shares are owned by company insiders. Comparatively, 5.3% of Maze Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Lexeo Therapeutics has higher earnings, but lower revenue than Maze Therapeutics. Maze Therapeutics is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.15	N/A
Maze Therapeutics	$167.50M	7.47	-$131.12M	-$2.52	N/A

Summary

Maze Therapeutics beats Lexeo Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Lexeo Therapeutics compare to Absci?

Absci (NASDAQ:ABSI) and Lexeo Therapeutics (NASDAQ:LXEO) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

Absci has a beta of 2.42, meaning that its share price is 142% more volatile than the broader market. Comparatively, Lexeo Therapeutics has a beta of 1.5, meaning that its share price is 50% more volatile than the broader market.

In the previous week, Absci had 1 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 3 mentions for Absci and 2 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 0.67 beat Absci's score of 0.56 indicating that Lexeo Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Absci	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lexeo Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lexeo Therapeutics has a net margin of 0.00% compared to Absci's net margin of -7,756.38%. Lexeo Therapeutics' return on equity of -41.85% beat Absci's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Absci	-7,756.38%	-61.71%	-54.52%
Lexeo Therapeutics	N/A	-41.85%	-38.03%

52.1% of Absci shares are owned by institutional investors. Comparatively, 60.7% of Lexeo Therapeutics shares are owned by institutional investors. 10.5% of Absci shares are owned by company insiders. Comparatively, 2.0% of Lexeo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Lexeo Therapeutics has lower revenue, but higher earnings than Absci. Absci is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Absci	$2.80M	591.44	-$115.18M	-$0.80	N/A
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.15	N/A

Absci presently has a consensus price target of $13.71, indicating a potential upside of 42.12%. Lexeo Therapeutics has a consensus price target of $18.75, indicating a potential upside of 346.43%. Given Lexeo Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Lexeo Therapeutics is more favorable than Absci.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Absci	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Lexeo Therapeutics beats Absci on 10 of the 16 factors compared between the two stocks.

How does Lexeo Therapeutics compare to First Tracks Biotherapeutics?

Lexeo Therapeutics (NASDAQ:LXEO) and First Tracks Biotherapeutics (NASDAQ:TRAX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations.

First Tracks Biotherapeutics is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.15	N/A
First Tracks Biotherapeutics	N/A	N/A	N/A	-$1.84	N/A

In the previous week, First Tracks Biotherapeutics had 2 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 4 mentions for First Tracks Biotherapeutics and 2 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 0.67 beat First Tracks Biotherapeutics' score of 0.14 indicating that Lexeo Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lexeo Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
First Tracks Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

60.7% of Lexeo Therapeutics shares are owned by institutional investors. 2.0% of Lexeo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

First Tracks Biotherapeutics' return on equity of 0.00% beat Lexeo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexeo Therapeutics	N/A	-41.85%	-38.03%
First Tracks Biotherapeutics	N/A	N/A	N/A

Lexeo Therapeutics presently has a consensus price target of $18.75, indicating a potential upside of 346.43%. First Tracks Biotherapeutics has a consensus price target of $66.55, indicating a potential upside of 72.40%. Given Lexeo Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Lexeo Therapeutics is more favorable than First Tracks Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00
First Tracks Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

Summary

Lexeo Therapeutics beats First Tracks Biotherapeutics on 7 of the 11 factors compared between the two stocks.

How does Lexeo Therapeutics compare to Vor Biopharma?

Lexeo Therapeutics (NASDAQ:LXEO) and Vor Biopharma (NASDAQ:VOR) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Vor Biopharma's return on equity of 0.00% beat Lexeo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexeo Therapeutics	N/A	-41.85%	-38.03%
Vor Biopharma	N/A	N/A	N/A

Lexeo Therapeutics has a beta of 1.5, meaning that its share price is 50% more volatile than the broader market. Comparatively, Vor Biopharma has a beta of 1.71, meaning that its share price is 71% more volatile than the broader market.

Lexeo Therapeutics presently has a consensus target price of $18.75, indicating a potential upside of 346.43%. Vor Biopharma has a consensus target price of $43.38, indicating a potential upside of 102.69%. Given Lexeo Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Lexeo Therapeutics is more favorable than Vor Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00
Vor Biopharma	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.91

60.7% of Lexeo Therapeutics shares are held by institutional investors. Comparatively, 97.3% of Vor Biopharma shares are held by institutional investors. 2.0% of Lexeo Therapeutics shares are held by insiders. Comparatively, 0.3% of Vor Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.15	N/A
Vor Biopharma	N/A	N/A	N/A	N/A	N/A

In the previous week, Lexeo Therapeutics and Lexeo Therapeutics both had 2 articles in the media. Lexeo Therapeutics' average media sentiment score of 0.67 beat Vor Biopharma's score of 0.00 indicating that Lexeo Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lexeo Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vor Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Lexeo Therapeutics and Vor Biopharma tied by winning 4 of the 8 factors compared between the two stocks.

How does Lexeo Therapeutics compare to Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Lexeo Therapeutics (NASDAQ:LXEO) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.

Lexeo Therapeutics has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Lexeo Therapeutics is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ultragenyx Pharmaceutical	$673M	2.13	-$575M	-$5.84	N/A
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.15	N/A

Ultragenyx Pharmaceutical presently has a consensus target price of $34.42, indicating a potential upside of 137.22%. Lexeo Therapeutics has a consensus target price of $18.75, indicating a potential upside of 346.43%. Given Lexeo Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Lexeo Therapeutics is more favorable than Ultragenyx Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ultragenyx Pharmaceutical	1 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.48
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Ultragenyx Pharmaceutical had 34 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 36 mentions for Ultragenyx Pharmaceutical and 2 mentions for Lexeo Therapeutics. Ultragenyx Pharmaceutical's average media sentiment score of 0.74 beat Lexeo Therapeutics' score of 0.67 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ultragenyx Pharmaceutical	12 Very Positive mention(s)	7 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Lexeo Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lexeo Therapeutics has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -81.79%. Lexeo Therapeutics' return on equity of -41.85% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ultragenyx Pharmaceutical	-81.79%	-1,024.42%	-44.40%
Lexeo Therapeutics	N/A	-41.85%	-38.03%

97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. Comparatively, 60.7% of Lexeo Therapeutics shares are held by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are held by company insiders. Comparatively, 2.0% of Lexeo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Ultragenyx Pharmaceutical has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market. Comparatively, Lexeo Therapeutics has a beta of 1.5, suggesting that its stock price is 50% more volatile than the broader market.

Summary

Lexeo Therapeutics beats Ultragenyx Pharmaceutical on 9 of the 16 factors compared between the two stocks.

Get Lexeo Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LXEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LXEO vs. The Competition

Export

Metric	Lexeo Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$344.59M	$3.89B	$7.25B	$12.95B
Dividend Yield	N/A	3.64%	2.57%	12.80%
P/E Ratio	-3.65	8.10	210.29	20.60
Price / Sales	N/A	1,456.59	656.37	93.45
Price / Cash	N/A	41.62	28.13	34.74
Price / Book	1.24	15.47	10.50	6.32
Net Income	-$99.96M	-$22.90M	$3.49B	$358.20M
7 Day Performance	-1.18%	-1.21%	0.59%	1.12%
1 Month Performance	-17.00%	-3.29%	-1.74%	-2.39%
1 Year Performance	-18.45%	37.74%	18.13%	5.35%

Lexeo Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LXEO Lexeo Therapeutics	2.0402 of 5 stars	$4.20 +0.5%	$18.75 +346.4%	-18.4%	$344.59M	N/A	N/A	59	News Coverage Positive News Analyst Upgrade Gap Down High Trading Volume
MAZE Maze Therapeutics	2.0688 of 5 stars	$24.36 -1.3%	$66.00 +170.9%	-1.8%	$1.35B	$20M	N/A	141	Negative News
ABSI Absci	2.7696 of 5 stars	$7.87 -2.8%	$13.71 +74.4%	+269.7%	$1.35B	$1.56M	N/A	140
TRAX First Tracks Biotherapeutics	2.6026 of 5 stars	$36.68 -2.4%	$63.00 +71.8%	N/A	$1.31B	N/A	N/A	104	News Coverage Analyst Forecast Gap Up
VOR Vor Biopharma	1.3286 of 5 stars	$22.17 -3.9%	$43.38 +95.6%	-21.4%	$1.31B	N/A	N/A	76	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LXEO) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lexeo Therapeutics (LXEO) Competitors

LXEO vs. MAZE, ABSI, TRAX, VOR, and RARE

How does Lexeo Therapeutics compare to Maze Therapeutics?

Summary

How does Lexeo Therapeutics compare to Absci?

Summary

How does Lexeo Therapeutics compare to First Tracks Biotherapeutics?

Summary

How does Lexeo Therapeutics compare to Vor Biopharma?

Summary

How does Lexeo Therapeutics compare to Ultragenyx Pharmaceutical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LXEO vs. The Competition

Lexeo Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lexeo Therapeutics (LXEO) Competitors

LXEO vs. MAZE, ABSI, TRAX, VOR, and RARE

How does Lexeo Therapeutics compare to Maze Therapeutics?

Is LXEO or MAZE more profitable?

Does the media favor LXEO or MAZE?

Which has more risk & volatility, LXEO or MAZE?

Do analysts rate LXEO or MAZE?

Do insiders & institutionals hold more shares of LXEO or MAZE?

Which has stronger valuation & earnings, LXEO or MAZE?

Summary

How does Lexeo Therapeutics compare to Absci?

Which has more volatility & risk, ABSI or LXEO?

Does the media refer more to ABSI or LXEO?

Is ABSI or LXEO more profitable?

Do insiders and institutionals have more ownership in ABSI or LXEO?

Which has stronger valuation and earnings, ABSI or LXEO?

Do analysts recommend ABSI or LXEO?

Summary

How does Lexeo Therapeutics compare to First Tracks Biotherapeutics?

Which has preferable earnings and valuation, LXEO or TRAX?

Does the media refer more to LXEO or TRAX?

Do insiders and institutionals believe in LXEO or TRAX?

Is LXEO or TRAX more profitable?

Do analysts rate LXEO or TRAX?

Summary

How does Lexeo Therapeutics compare to Vor Biopharma?

Is LXEO or VOR more profitable?

Which has more risk & volatility, LXEO or VOR?

Do analysts prefer LXEO or VOR?

Do institutionals & insiders have more ownership in LXEO or VOR?

Which has preferable valuation and earnings, LXEO or VOR?

Does the media prefer LXEO or VOR?

Summary

How does Lexeo Therapeutics compare to Ultragenyx Pharmaceutical?

Which has preferable earnings and valuation, RARE or LXEO?

Do analysts recommend RARE or LXEO?

Does the media favor RARE or LXEO?

Is RARE or LXEO more profitable?

Do institutionals & insiders believe in RARE or LXEO?

Which has more risk and volatility, RARE or LXEO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LXEO vs. The Competition

Lexeo Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools